SimBioSys developed a simulation engine, TumorScope,[1] which utilizes current standard of care diagnostic data (imaging & pathology) to create spatially resolved virtual replicas of an individual tumor and microenvironment and uses mechanistic models to incorporate the major hallmarks of cancer including drug sensitivity & delivery, metabolism, mechanical forces.
The simulations enable precise & comprehensive predictions of response to therapy while providing researchers and clinicians keys insights into mechanisms of resistance.
The first indication to market will be Early Stage Breast Cancer where there is significant opportunity to improve outcomes by selecting the right first line therapy while de-escalating care and lowering costs and side effects.
A recent pivotal study at University of Chicago, TumorScope™ produced 91% sensitivity and 93% specificity rates of predicting complete response to the physician's choice of therapy at the time of diagnosis.
SimBioSys anticipates FDA clearance for its breast cancer surgical planning tool in late 2023 with an expansion to other solid tumors to follow.